Chemomab Therapeutics (CMMB) Retained Earnings (2017 - 2025)

Chemomab Therapeutics (CMMB) has 9 years of Retained Earnings data on file, last reported at -$111.6 million in Q4 2025.

• For the quarter ending Q4 2025, Retained Earnings fell 8.77% year-over-year to -$111.6 million; the trailing twelve-month figure through Dec 2025 stood at -$111.6 million (down 8.77% YoY), and the FY2025 full-year result was -$111.6 million, down 8.77% from the prior year.
• Retained Earnings for Q4 2025 stood at -$111.6 million, down from -$109.7 million in the prior quarter.
• Across five years, Retained Earnings topped out at -$25.4 million in Q1 2021 and bottomed at -$111.6 million in Q4 2025.
• The 5-year median for Retained Earnings is -$82.6 million (2023), against an average of -$74.1 million.
• The widest annual swing landed in 2021, when Retained Earnings surged 76.69%; it then slumped 78.4% in 2022.
• A 5-year view of Retained Earnings shows it stood at -$36.2 million in 2021, then slumped by 76.43% to -$63.8 million in 2022, then sank by 38.95% to -$88.7 million in 2023, then slipped by 15.73% to -$102.6 million in 2024, then dropped by 8.77% to -$111.6 million in 2025.
• The last three Retained Earnings figures came in at -$111.6 million (Q4 2025), -$109.7 million (Q3 2025), and -$108.0 million (Q2 2025), per Business Quant data.

Peer Comparison